Mismatch negativity impairment is associated with deficits in identifying real-world environmental sounds in schizophrenia

Joshi, Yash B.; Breitenstein, Barbara; Tarasenko, Melissa; Michael, Thomas; Chang, Weijie; Sprock, Joyce; Sharp, Richard F.; Light, Gregory A.

doi:10.1016/j.schres.2017.05.020

Cited by 26 publications

(20 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Deficits in EAP have been extensively studied in patients with schizophrenia, where they are thought to contribute to failures in detecting important environmental cues and filtering of irrelevant stimuli, possibly leading to social withdrawal, hallucinations, cognitive dysfunction, and decreased level of overall day-to-day functioning (1,3,4,6,7,9,10,12,19,88,100,114,168). Here, we reviewed studies examining if MMN and P50 meet the 5 criteria for a marker to be considered an endophenotype (46), as well as their relationship with cognitive and psychosocial functioning to examine their potential to be used as markers to inform interventions targeted at improving these domains.…”

Section: Discussionmentioning

confidence: 99%

“…Impairment in MMN is consistently demonstrated in patients with schizophrenia (14,19,88) with studies showing moderate to high test-retest reliability (58,89). However, studies examining heritability, trait stability and diagnostic specificity of MMN have reported mixed findings (89,90,100) suggesting that while promising, future studies further demonstrating MMN's suitability as an endophenotype for schizophrenia would be beneficial.…”

Section: Discussionmentioning

confidence: 99%

“…A large body of studies has demonstrated decreased MMN in schizophrenia using different deviant stimuli, with one study reporting an effect size of 0.99 between patients and healthy controls (19,22,23,67,87,88). MMN also has good test-retest ability, with studies reporting moderate to high interclass correlation coefficients (ICC) (22,58,89).…”

Section: Mismatch Negativitymentioning

confidence: 99%

“…For example, MMN amplitude change produced by duration and intensity deviance are identifiable in earlier stages of schizophrenia, while amplitude changes to frequency deviance may become more prominent in later stages of the illness (64,93). The association between poor performance on cognitive tests and MMN amplitude abnormalities in patients with schizophrenia may have implications for daily functioning, as MMN deficits were found to be correlated with greater errors in identification of environmental sounds that are functionally relevant (19). Also, patients with higher MMN amplitude showed greater improvement after auditory perceptual training exercises, suggesting that MMN may be used as a predictive marker in schizophrenia as well (107).…”

Section: Mismatch Negativitymentioning

confidence: 99%

See 3 more Smart Citations

Neurophysiological Biomarkers in Schizophrenia—P50, Mismatch Negativity, and TMS-EMG and TMS-EEG

2020

View full text Add to dashboard Cite

Impaired early auditory processing is a well characterized finding in schizophrenia that is theorized to contribute to clinical symptoms, cognitive impairment, and social dysfunction in patients. Two neurophysiological measures of early auditory processing, P50 gating ("P50") and mismatch negativity (MMN), which measure sensory gating and detection of change in auditory stimuli, respectively, are consistently shown to be impaired in patients with schizophrenia. Transcranial magnetic stimulation (TMS) may also be a potential method by which sensory processing can be assessed, since TMS paradigms can be used to measure GABA B-mediated cortical inhibition that is linked with sensory gating. In this review, we examine the potential of P50, MMN and two TMS paradigms, cortical silent period (CSP) and long-interval intracortical inhibition (LICI), as endophenotypes as well as their ability to be used as predictive markers for interventions targeted at cognitive and psychosocial functioning. Studies consistently support a link between MMN, P50, and cognitive dysfunction, with robust evidence for a link between MMN and psychosocial functioning in schizophrenia as well. Importantly, studies have demonstrated that MMN can be used to predict performance in social and cognitive training tasks. A growing body of studies also supports the potential of MMN to be used as an endophenotype, and future studies are needed to determine if MMN can be used as an endophenotype specifically in schizophrenia. P50, however, has weaker evidence supporting its use as an endophenotype. While CSP and LICI are not as extensively investigated, growing evidence is supporting their potential to be used as an endophenotype in schizophrenia. Future studies that assess the ability of P50, MMN, and TMS neurophysiological measures to predict performance in cognitive and social training programs may identify markers that inform clinical decisions in the treatment of neurocognitive impairments in schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Mismatch Negativitymentioning

confidence: 99%

Section: Mismatch Negativitymentioning

confidence: 99%

See 2 more Smart Citations

Neurophysiological Biomarkers in Schizophrenia—P50, Mismatch Negativity, and TMS-EMG and TMS-EEG

2020

View full text Add to dashboard Cite

show abstract

“…Reduction of auditory MMN amplitude was reported over two decades ago in SZ and has been replicated numerous times ( 37 ). MMN deficits are found in those with chronic psychosis ( 27 , 37 – 50 ), in unmedicated SZ patients ( 29 , 40 , 46 , 47 , 51 , 52 ), and are shown to be resistant to antipsychotics ( 46 , 53 – 58 ). Abnormal MMN is also found in recent-onset psychosis as well as prodromal illness ( 30 , 51 , 59 – 66 ).…”

Section: Mismatch Negativity: a Neurophysiological Biomarker For Earlmentioning

confidence: 99%

Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia

Joshi

Light

2018

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.

show abstract

Emotional Experience of People With Schizophrenia and People at Risk for Psychosis

Riehle,

Straková,

Lincoln

2024

JAMA Psychiatry

View full text Add to dashboard Cite

ImportancePsychotic symptoms are associated with subjective reports of aberrant emotion, such as excessive fear or anhedonia, but whether these aberrations reflect aberrant emotional experience of normative stimuli is uncertain both for individuals with schizophrenia and those at risk for psychosis.ObjectiveTo provide a meta-analysis of study samples of emotional experience in individuals with schizophrenia and those at risk for psychosis as assessed in laboratory-based emotion-induction studies.Data SourcesMEDLINE and PsycINFO databases were searched for articles published from January 1986 and Google Scholar citations of a relevant earlier meta-analysis until August 2022. Reference lists were manually searched for additional studies.Study SelectionIncluded studies measured positive or negative emotional experience in response to standardized emotionally evocative stimuli and compared participants diagnosed with schizophrenia or participants at risk for psychosis with healthy controls.Data Extraction and SynthesisThe meta-analysis was registered with PROSPERO and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. Data were extracted by 2 independent coders, and random-effects analyses were conducted.Main Outcomes and MeasuresOutcomes were 3 scales of emotional experience (unipolar positive emotion, unipolar negative emotion, bipolar valence), analyzed separately for pleasant, neutral, and unpleasant stimuli. A meta-analysis was conducted for differences between the 2 clinical groups combined and controls. Subgroup differences (schizophrenia vs at risk) and the influence of several other variables were tested in moderator analyses.ResultsThis systematic review and meta-analysis included data from 111 studies and 6913 participants (schizophrenia: 2848 [41.2%]; at risk: 877 [12.7%]; healthy controls: 3188 [46.1%]). Compared with controls, people with schizophrenia and those at risk for psychosis experienced pleasant stimuli as less positive (unipolar positive: standardized mean difference [SMD] Hedges g = −0.19; P =.001; bipolar valence: SMD Hedges g = −0.28; P &lt;.001) and more negative (Hedges g = 0.52; P &lt;.001), neutral stimuli as more negative (Hedges g = 0.55; P &lt;.001), and unpleasant stimuli as both more positive (unipolar positive: SMD Hedges g = 0.23; P =.005; bipolar valence: Hedges g = 0.12; P =.01) and more negative (Hedges g = 0.22; P &lt;.001). Moderator analyses indicated a less aberrant emotional experience for odors than for visual stimuli (unipolar negative, pleasant z score = −2.97; P =.003; unipolar negative, neutral z score = −2.70; P =.007), an association between higher negative symptoms and diminished positive emotion for pleasant stimuli in schizophrenia (z score = −2.98; P =.003), and that subgroup differences were limited to neutral stimuli.Conclusions and RelevanceResults suggest a pattern of aberrant emotional experience of normative stimuli in schizophrenia and that this already was observable before disorder onset. In particular, the aberrant experience of pleasant stimuli needs to be considered as an intervention target.

show abstract

Mismatch negativity impairment is associated with deficits in identifying real-world environmental sounds in schizophrenia

Cited by 26 publications

References 45 publications

Neurophysiological Biomarkers in Schizophrenia—P50, Mismatch Negativity, and TMS-EMG and TMS-EEG

Neurophysiological Biomarkers in Schizophrenia—P50, Mismatch Negativity, and TMS-EMG and TMS-EEG

Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia

Emotional Experience of People With Schizophrenia and People at Risk for Psychosis

Contact Info

Product

Resources

About